- Conditions
- Healthy Volunteers
- Interventions
- RO7890597, Placebo, Rabeprazole, Itraconazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 7,030
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- ARRY-502, Placebo
- Drug
- Lead sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Pain
- Interventions
- Painful Stimuli
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 21 Years to 44 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Amyloidosis
- Interventions
- 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Moderate Hepatic Impairment
- Interventions
- Pexidartinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Pharmacokinetics
- Interventions
- Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- Mario Castro, MD, MPH
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
- Interventions
- Sporanox, Diclofenac Sodium
- Drug
- Lead sponsor
- Javelin Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
- Conditions
- Healthy, Salivary Gland Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- PF-04171327 25 mg, Midazolam 2 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Marburg Hemorrhagic Fever
- Interventions
- AVI-6003, Placebo
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy
- Interventions
- ZD03, Placebo
- Drug · Other
- Lead sponsor
- Shanxi Zhendong Leading Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Focal Hand Dystonia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Gait Training, Locomotion
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- tenofovir, emtricitabine, atazanavir, ritonavir
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy
- Interventions
- IMA-026
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- Lumos Labs, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Safety of Neosaxitoxin in Healthy Volunteers
- Interventions
- Neosaxitoxin in saline, NeoSTX + bupivacaine 0.2%, NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml, Saline placebo
- Drug · Other
- Lead sponsor
- Charles Berde
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Intracranial Central Nervous System Disorder, Mental Disorder, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 6 Years to 90 Years
- Enrollment
- 949 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer Disease, Healthy
- Interventions
- LY3372993, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Cypress, California • Long Beach, California • DeLand, Florida + 6 more
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- CS0159
- Drug
- Lead sponsor
- Cascade Pharmaceuticals, Inc
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Healthy
- Interventions
- Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 2
- States / cities
- Saint Charles, Missouri • Houston, Texas